The next Ask the Scientist webinar will feature Michelle Troche, Ph.D., discussing developing treatments for swallowing and communication deficits in progressive supranuclear palsy (PSP). It will take place on Thursday, September 3, 2020, at 12:00 p.m. Eastern Daylight Time (9 a.m. PDT)
Dr. Troche currently serves as an associate professor of speech and language pathology in the Communication Sciences and Disorders Program, Department of Biobehavioral Sciences at Teachers College, Columbia University. She also holds adjunct positions in the Departments of Neurology and Otolaryngology, and she directs and is the principal investigator for the college’s Laboratory for the Study of Upper Airway Dysfunction.
This webinar is technical in nature and is intended for research and healthcare professionals. Any medications that are referred to in this presentation should not be tried unless under the supervision of a licensed professional.
The presentation will be 40 minutes long, followed by 15 minutes for asking questions and providing answers. Questions may be emailed to firstname.lastname@example.org or submitted during the registration process.
The registration link will be emailed out one hour before the beginning of the event and again ten minutes before the event. This webinar will be recorded.
Dr. Troche’s research is aimed at developing robust evaluation and treatment techniques for dystussia (disordered cough) and dysphagia (swallowing difficulties). Her research has been funded by the National Institutes of Health (NIH), Michael J. Fox Foundation, and National Ataxia Foundation. In 2016, she was awarded a CurePSP Venture Grant supported by The Jasperson Legacy Fund.
CurePSP, Inc. is a nonprofit organization (501 (c)(3) organization) working to increase awareness, advocate for patients and families, and fund research for devastating prime of life neurodegenerative diseases, including progressive supranuclear palsy (PSP). Since 1990, it has provided funding to more than 200 researchers for a cumulative investment of $20 million. CurePSP's objective is to provide scientists with seed funding opportunities so they can develop the necessary proof of concept to validate innovative ideas and qualify for larger funding sources. Funds are awarded to researchers focusing on the underlying molecular and cellular mechanisms of PSP, CBD, and other neurodegenerative disorders. The organization also aims to enable researchers to focus on translational clinical studies involving patients.
This webinar is available because of the support of various viewers. To support CurePSP's mission of care, consciousness, and cure please go to this link or add a donation during registration!